Mabwell has declared that its fully-owned subsidiary, T-mab, has successfully received the green light for its Denosumab Injection from the National Medical Products Administration.

As the potential of molecular glue technology becomes increasingly apparent, pharmaceutical companies are beginning to invest more heavily in this area.

Primary Objectives Achieved in Stage 3 Trial for HLX14, a Biosimilar Contender to Prolia® and Xgeva® (denosumab).

April 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Ferring Unveils Key Phase 3 Results for Experimental Therapy, SI-6603 (condoliase), in Treating Lower Back Disc Protrusion during ASIPP 2024.

April 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Opioid receptors are crucial for pain relief, blocking pain signal transmission to reduce acute and chronic pain like post-surgery and cancer pain.

April 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

On March 28th, Genfleet Therapeutics publicly announced a patent for an oral KRAS G12D inhibitor, with the patent number WO2024061370A1.

U.S. Sanctions ENHERTU®, a Pioneer HER2-Targeting Drug, for Metastatic Solid Cancers with HER2 Positivity After Initial Treatments.

Bitopic ligands of GPCRs (G protein-coupled receptors) refer to a single chemical entity composed of two pharmacophoric groups covalently linked together.

FDA Clears Abecma from Bristol Myers and 2seventy bio for Treatment of Relapsed or Stubborn Multiple Myeloma Following Two Previous Therapies.